• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN
July 3, 2025 10:20 AM EDT
Manufacturing

Tor­rent Phar­ma’s $1.38B JB Chem­i­cals takeover; Fu­ture Pak to buy Ther­at­e­ch­nolo­gies

Anna Brown

News Reporter

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more.

Tor­rent Phar­ma­ceu­ti­cals will

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

more like this

  • Ex­clu­sive: Ger­man CD­MO BioSpring em­barks on €100M+ nu­cle­ic acid fac­to­ry July 3, 2025
  • Hik­ma pledges $1B to ex­pand US man­u­fac­tur­ing pres­ence June 30, 2025
  • Uni­cy­cive gets a CRL for chron­ic kid­ney dis­ease pill as third-par­ty pro­duc­tion is­sues linger June 30, 2025
TRENDING NOW

No­var­tis' Cosen­tyx fails Phase 3 study for au­toim­mune dis­ease

Chi­na’s rise splits US biotech in­vestors: Cash in, or counter? 

Now pri­vate, blue­bird bio con­tin­ues lead­er­ship re­vamp; Roche R&D ex­ec an­nounces re­tire­ment

Num­ber of megarounds drops 38% in first half as biotechs strug­gle against wors­en­ing slump

Struc­ture in part­ner­ing talks for GLP-1 pill as mid-stage read­out nears

HHS ac­tions to re­move web con­tent were ar­bi­trary, 'poor­ly thought-through,' judge rules

Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times